Ron Alfa

CEO & Co-founder @NOETIK_AI
Using AI to actually solve cancer.
Ex-@RecursionPharma | Stanford MD-PhD

[Ron Alfa @Ronalfa]

1/ Spatial transcriptomics is among the richest view of human biology that we have: 18,963 genes mapped at subcellular resolution.

It's also almost never collected outside of research settings.

So we trained a foundation model to generate it from a clinical H&E image alone.

Meet TARIO-2. 🧵

https://t.co/hcTMjUkCjw

[Ron Alfa @Ronalfa]

@bauer_lesavage @_DimensionCap @NOETIK_ai 🙏

[Ron Alfa @Ronalfa]

Another great research piece by @_DimensionCap @bauer_lesavage on Training Data for Bio AI.

Models will only be as good as the underlying data, and the biology they learn will be constrained by the limitations of that data.

We need to think deeply about scaling the best quality data to solve human bio with AI. Our thesis from day 1 at @NOETIK_ai.

[Bauer LeSavage @bauer_lesavage]

The training data market has exploded for LLMs and bio foundation models are next.

But biological data is extremely complex and requires a data generation playbook that prioritizes quality over immediate scale.

@_DimensionCap Research article live now!

https://t.co/3CqSYADLJP

[Ron Alfa @Ronalfa]

@bauer_lesavage @_DimensionCap Great piece, and very timely.

[Ron Alfa @Ronalfa]

Sometimes robots screw up too.

The tumor cores are not positioned deep into the block. Our histology guru fixed it.

[Ron Alfa @Ronalfa]

Chris Boerner CEO, BMS: AI will let us discover new subtypes of lung cancer and target drugs to those subtypes.

Stanford AI Life Sciences Symposium

[Ron Alfa @Ronalfa]

@jacobkimmel Still want to do that social.

[Ron Alfa @Ronalfa]

massive!

[Jacob Kimmel @jacobkimmel]

on day 1 @newlimit, we imagined it would take 10+ years to invent real medicines.

our recent results have accelerated the timeline to next year. we've raised a Series C led by @foundersfund alongside @ThriveCapital, @Greenoaks, and many others to bring therapies to the clinic.

medicines for aging are among the most valuable possible technologies. we are grateful to our partners for the opportunity to pursue this mission.

[Ron Alfa @Ronalfa]

This is the era for biology.

[NewLimit @newlimit]

Following breakthrough results, we’re bringing longevity medicine to human trials.

We’ve raised a $435M Series C led by @foundersfund to make it happen.

Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.

[Ron Alfa @Ronalfa]

@honicky 💯

[Ron Alfa @Ronalfa]

@ChrisHayduk @NOETIK_ai @Agenus_Bio ‼️ We’ve been expanding data very quickly across all cancers.

[Ron Alfa @Ronalfa]

This weekend at ASCO, we shared first results using @NOETIK_ai TARIO-2 foundation models to predict patients likely to benefit using pre-treatment H&E alone (from actual clinical trial data with @Agenus_Bio!).

Some highlights below!

[Ron Alfa @Ronalfa]

@Melissabime @NOETIK_ai @Agenus_Bio None of the H&E from the Agenus trial are in the training set. These were not produced in our labs (where all our training data is produced), they come from the clinical trial.

[Ron Alfa @Ronalfa]

These results show the impact of our foundation models on the most critical problem in therapeutics: predicting clinical benefit in patients.

Imagine deploying these capabilities to enable a drug program directly!

More results in the poster (now online), and even more coming soon:

https://t.co/6lhx4o4SMm

[Ron Alfa @Ronalfa]

We also benchmarked TARIO-2 results against state-of-the-art open pathology foundation models in 49 MSS mCRC:

TARIO-2 achieved the strongest performance for both endpoints:

BOR AUROC: 0.81 vs 0.68 / 0.53
OS C-index: 0.67 vs 0.58 / 0.54

[Ron Alfa @Ronalfa]

@ThatMrE Yes

[Ron Alfa @Ronalfa]

You can sell insurance to startups, or you can cure pancreatic cancer.

[Ron Alfa @Ronalfa]

@outerspaceisaac Every couple weeks…